Novo Nordisk's stock dropped 18% after a phase three trial for its CagriSema weight loss drug yielded results below expectations. The drug, combining semaglutide and Cagrilintide, ...
Novo Nordisk plans to invest $1.23 billion in a new Danish facility to support rare disease treatments, creating jobs and reinforcing its commitment to innovation and Danish roots.
Novo Nordisk's shares dropped over 2% after a preprint study linked Ozempic to a rare vision condition. The study, by scholars from Norway and Denmark, found Ozempic users were twi...
